[aarontech] giving blind people their sight?

  • From: "Valiant8086 \(on laptop\)" <valiant8086@xxxxxxxxxxx>
  • To: <aarontech@xxxxxxxxxxxxx>
  • Date: Wed, 7 May 2008 00:17:42 -0400

Forwarded from the blind cool tech mailing list.
----- Original Message ----- From: "Neal Ewers" <neal.ewers@xxxxxxxxxxxxxx>
To: "Bct" <bct@xxxxxxxxxxxxxxxxxxxxxx>
Sent: Tuesday, May 06, 2008 2:18 PM
Subject: [BCT] OT, giving blind people their sight?


Gene therapy experiments improve vision in nearly blind

By STEPHANIE NANO

The Associated Press

Sunday, April 27, 2008; 5:36 PM


<http://www.washingtonpost.com/wp-dyn/content/article/2008/04/27/AR200804270
1>
http://www.washingtonpost.com/wp-dyn/content/article/2008/04/27/AR2008042701

326_pf.html



NEW YORK -- Scientists for the first time have used gene therapy to
dramatically improve sight in people with a rare form of blindness, a
development experts called a major advance for the experimental technique.

Some vision was restored in four of the six young people who got the
treatment, teams of researchers in the United States and Britain reported
Sunday. Two of the volunteers who could only see hand motions were able to
read a few lines of an eye chart within weeks.

"It's a phenomenal breakthrough," said Stephen Rose, chief research officer of the Foundation Fighting Blindness, which helped pay for one study done at
Children's Hospital of Philadelphia.

If successful in larger numbers, experts said, the technique has the
potential to reverse blindness from other kinds of inherited eye diseases.

"I think this is incredibly exciting," said Dr. Jean Bennett, a professor of
ophthalmology at the University of Pennsylvania and a leader of the
Philadelphia study. "It's the beginning of a whole new phase of studies."

The research was published online Sunday by the New England Journal of
Medicine in conjunction with presentations at a medical meeting in Florida.

The two teams of scientists, working separately, each tested gene
replacement therapy in three patients with a form of a rare hereditary eye
disease called Leber's congenital amaurosis. There's no treatment for the
disease, which appears early in infancy and causes severe vision loss,
especially at night.

An estimated 2,000 Americans have the form of the disease they targeted,
Bennett said.

Gene therapy _ replacing faulty genes with a normal version _ has been
studied in humans for over 15 years with limited success. The field suffered a setback with the 1999 death of Jesse Gelsinger, 18, in an experiment for a
liver disorder at Penn. And some children treated for an immune disorder
called the "bubble boy disease" later developed leukemia.

The early results of the eye experiments should give the field a boost, some
experts said.

"I think it's really a big shot in the arm for gene therapy and for medicine
in general," said Dr. Ronald Crystal, head of genetic medicine at Weill
Cornell Medical College in New York.

Each of the study participants had mutations in a gene that makes a protein
needed by the retina, which senses light and sends images to the brain.

Those without the gene gradually lose sight until they are blind in early
adulthood.

The retina itself stays in relatively good shape for a while, making it a
good candidate for gene therapy, said Robin Ali, a professor at University
College London, who led the British team. He likened the defective gene to a
missing spark plug in a car engine.

"The whole engine can be absolutely fine, but if it doesn't have a spark
plug, the car's not going to work," said Ali.

For the experiment, the scientists injected millions of copies of a working
gene beneath the retina in the back of the eye. Only one eye was treated _
the worst one _ in case anything went wrong; the untreated eye was used for
comparison. After the treatment, their eyesight and light sensitivity were
measured periodically; mobility was tested in a maze or an obstacle course.

All three of those treated in Philadelphia showed significant improvement in
their vision, the researchers said. The volunteers _ two women, 19 and 26,
and a man, 26 _ were from Italy, where they had been screened by researchers
there. The longest follow-up was six months.

Besides reading lines on an eye chart, they could see better in dim lit,
Bennett said.

"We were not expecting to restore their vision to 20/20," she said.

In the British group, the treatment only worked in 18-year-old Steven
Howarth, whose disease was less advanced than the other two _ a girl, 17;
and a man, 23, who was followed for a year.

Howarth said he used to rush home from school because he was worried about
getting around in the dark, according to remarks issued by the university.

"Now, my sight when it's getting dark or it's badly lit is definitely
better. It's a small change _ but it makes a big difference to me," said
Howarth, who lives in Bolton, near Manchester.

After the injection last July, Howarth said his eye felt like sandpaper. It was better after a week, and his eyesight gradually improved. He was able to negotiate a dimly lit maze in 14 seconds without bumping into any obstacles;
before it took him 77 seconds with eight errors.

There were no serious side effects reported in either group. One of the
patients in Philadelphia developed a hole in his retina which didn't affect his eyesight. The researchers think the hole was related to the surgery and
not the injected gene.

The researchers said there was no evidence that the altered virus used to
ferry the gene into the retina's cells had traveled outside the eye to other
areas of the body.

The groups have each treated a fourth patient, including a preteen in
England. The researchers hope to see better results with higher doses and in
younger patients with less eye damage.

The National Eye Institute is funding a third similar study at the
University of Florida.

The research in Philadelphia and London was paid for by a variety of
government agencies and private foundations. An employee of Targeted
Genetics Corp., which made the altered virus used in London, is a co-author
of their report. Four of the Philadelphia researchers, including Bennett,
have either applied for or have patents related to gene therapy. Ali and
another British researcher have also applied for a patent for the procedure.

___

AP Science Writer Malcolm Ritter contributed to this report.

___

On the Net:

New England Journal of Medicine: <http://www.nejm.org/> http://www.nejm.org

National Eye Institute:  <http://www.nei.nih.gov/> http://www.nei.nih.gov


Neal Ewers
Ravenswood Productions
Madison Wisconsin
Local phone: 608-277-1995
Toll Free: 888-544-8332
email: neal.ewers@xxxxxxxxxxxxxx
Web: http://ravenswood.org <http://ravenswood.org/>
FTP site: ftp://ftp.ravenswood.org <ftp://ftp.ravenswood.org/>
Skype name:  neal163

_______________________________________________
BCT mailing list
BCT@xxxxxxxxxxxxxxxxxxxxxx
http://lists.blind-planet.com/listinfo.cgi/bct-blind-planet.com


--
No virus found in this incoming message.
Checked by AVG.
Version: 7.5.524 / Virus Database: 269.23.9/1417 - Release Date: 5/6/2008 8:07 AM




Other related posts: